- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Lawrence Shulman Discusses the Role of Rising Drug Costs in Value-Based Care
Lawrence N. Shulman, MD, director of the Center for Global Cancer Medicine at the Abramson Cancer Center, and professor of Medicine at the Hospital of the University of Pennsylvania, explains how providers are reacting to more effective, more costly therapies entering the cancer landscape.
Lawrence N. Shulman, MD, director of the Center for Global Cancer Medicine at the Abramson Cancer Center, and professor of Medicine at the Hospital of the University of Pennsylvania, explains how providers are reacting to more effective, more costly therapies entering the cancer landscape.
Transcript
As drug costs continue to rise, is value-based care changing the way providers make treatment decisions for patients with cancer?
I think the good news is, over the last couple of years, we’ve had a lot of new cancer therapies, which have radically changed the prognosis for our patients in diseases like melanoma and lung cancer. But, I think we all know those new treatments have come with a huge cost. They are so much better in so many cases than our old treatments. I don’t think oncologists or other specialists, in fact, make decisions based on cost. They make decisions based on what the best therapies are that are available for their patients, and particularly when there’s a big difference between the new therapy and the old therapy.
Sequencing CAR T and Bispecifics for Multiple Myeloma: Tyler Sandahl, PharmD
July 8th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, while bispecific antibodies are reserved for later lines or for patients unable to tolerate CAR T.
Read More
Insurance Gaps Threaten Cancer Treatment Success
July 7th 2025Access to and affordability of immune checkpoint inhibitors, which can be lifesaving if patients receive them on time and under optimal circumstances, continue to top the list of reasons behind outcomes disparities for patients who have private insurance vs those who remain uninsured.
Read More
